PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › 18F-FDG

Drugs in development · updated 30 October 2026

18F-FDG: clinical trials and development status

Other names and codes: ^1^8F-fluorodeoxyglucose, Fludeoxyglucose F-18

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 18F-FDG is in 22 active clinical trials (recruiting or ongoing, phases I–III) for 29 diseases. The most advanced phase is III.

22Active trials
IIIMost advanced phase
29Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow 18F-FDG and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Breast neoplasmII7NCT07848243
Prostatic NeoplasmsII3NCT03173924
Stomach neoplasmII3NCT06503146
NeoplasmII2NCT06956391
Bladder neoplasmII1NCT06503146
CholangiocarcinomaII1NCT06503146
CraniopharyngiomaII1NCT01419067
EpendymomaII1NCT02125786
Gastrointestinal neoplasmII1NCT07848243
Hepatocellular carcinomaII1NCT06503146
Lung neoplasmII1NCT07848243
Lung small cell carcinomaII1NCT06503146
MelanomaII1NCT07848243
MesotheliomaII1NCT06503146
MetastasisII1NCT07285993
Non-small-cell lung carcinomaII1NCT07848243
Ovarian neoplasmII1NCT06503146
ParagangliomaII1NCT06503146
PheochromocytomaII1NCT06503146
Renal cell carcinomaII1NCT06613269
SarcomaII1NCT06503146
Cardiovascular diseaseI3NCT07838649
CardiotoxicityI1NCT07838649
Hodgkin lymphomaI1NCT07838649
Non-Hodgkin lymphomaI1NCT07838649
Pulmonary fibrosisI1NCT05121779
Transitional cell carcinomaEarly I2NCT07023861
Brain NeoplasmsEarly I1NCT05549024
Multiple myelomaEarly I1NCT06717113

Everything on 18F-FDG

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch